The human microbiome – the collection of bacteria, viruses, fungi, and other microorganisms that live inside and on the surface of our bodies – has garnered significant scientific interest in recent years. The Human Microbiome Project (HMP), which was launched in 2007, seeks to characterize the diverse microbiota to help understand how these microbes impact human health and disease. Initial results from the HMP predict that over 10,000 microbial species coexist within the human ecosystem.Read More
The lung cancer death rate—the number of lung cancer deaths per 100,000 U.S. men and women—has been decreasing slowly but steadily in the United States for the past 25 years. The latest National Cancer Institute (NCI) data show that it declined 31 percent from a high of 59.1 lung cancer deaths per 100,000 U.S. men and women in 1993 to 40.6 in 2015.Read More
As a monthly feature on this blog, we spotlight the 10 articles selected by our editors from each journal issue published by the American Association of Cancer Research (AACR). These journals feature original articles spanning the continuum of cancer research, from basic science discoveries to patient care.Read More
The American Association for Cancer Research (AACR) began publishing scientific articles in 1916, and now proudly publishes eight peer-reviewed journals which cover a diverse array of cancer-related topics. The editors …Read More
Anthracyclines, a widely used class of chemotherapeutics, work in several ways to kill rapidly dividing cells, including those found in a tumor. While these drugs are commonly used to treat many types of adult and childhood cancer, they have a detrimental side effect – cardiotoxicity.
The cardiotoxicity of anthracyclines is dose-dependent; the more exposure patients have to the drug, the more serious risk they carry for heart-related problems. This can represent a unique challenge in children treated with anthracyclines, whose hearts are still developing.Read More
Biopsies have been an integral part of cancer care for decades. In undiagnosed patients, oncologists can examine suspicious tissues and determine if the cells are benign or malignant. Following diagnosis, biopsies can reveal additional information about a patient’s tumor – What mutations are driving this cancer? Is this patient likely to respond to a particular therapy? In cases of cancer recurrence, biopsies can provide further information – Has this patient become resistant to treatment? Is the tumor driven by different mutations?Read More
Each month, the American Association for Cancer Research (AACR) publishes 10 articles from its eight esteemed scientific journals, showcasing some of the leading discoveries in cancer research. Read on to learn about the editors’ selections from this month. All articles featured are freely available for a limited time.Read More
The American Association for Cancer Research (AACR) publishes eight esteemed scientific journals. Each month, these journals feature a wide range of peer-reviewed research that encompasses the entire spectrum of cancer science. Some of the world’s leading cancer scientists publish articles in our journals, contributing greatly toward the AACR’s mission to prevent and cure cancer through research, education, communication, and collaboration.
We are pleased to debut a new feature on the blog, Editors’ Picks. Each month, AACR journal editors will share a curated list of original articles, representing each publication. While our journals are subscription-based, the stories featured in Editors’ Picks will be freely available for the month.Read More
This week, President Trump signed the Childhood Cancer Survivorship, Treatment, Access and Research (STAR) Act, which is aimed at supporting pediatric cancer research. The legislation calls for expanding the collection of patient biospecimens and records, improving surveillance, and investigating pediatric survivorship.Read More
Assessing new anticancer therapeutics in clinical trials is a vital step in evaluating the toxicity and efficacy of treatment before its approval for widespread use. Throughout these trials, many patients encounter a variety of side effects, ranging from physical ailments such as nausea or rash to psychological symptoms such as depression or anxiety. While it is standard practice to record clinician-reported outcomes to characterize safety, there is no current standard requirement for the use of patient-reported outcomes (PROs) in cancer clinical trials.Read More